Aditxt, Inc. (ADTX): R&D Expense
$3.19M
Year ended 2025-12-31
$3.03M
Trailing 12 months to 2026-03-31
-24.0%
3-year compound annual growth
+27.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.19M | -70.7% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $10.89M | +53.9% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $7.07M | -2.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $7.27M | +44.1% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $5.04M | +437.6% | 2023-04-17, From 2021-01-01 |
| 2020-12-31 | $938.0K | +434.6% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $175.4K | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | 2025-12-31 | $3.19M | -70.7% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $923.9K | +540.0% |
| Genelux Corp (GNLX) | 2025-12-31 | $19.85M | +4.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $340.0K | +22.3% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
Compare ADTX, TCRT, ASBP, GNLX side by side · Screen every company in Pharmaceutical Preparations ↗